Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Courtney V Fletcher

Showing results (131-140 of 162) with videos related to

Pageof 17
Sort By:
Nature|January 28, 2016
Persistent HIV-1 replication maintains the tissue reservoir during therapyRamon Lorenzo-Redondo, Helen R Fryer, Trevor Bedford, et al.
Pathogens & Immunity|May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 TrialKatya C Corado, Kara W Chew, Mark J Giganti, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
CD8+ cells and small viral reservoirs facilitate post-ART control of SIV in Mauritian cynomolgus macaquesOlivia E Harwood, Lea M Matschke, Ryan V Moriarty, et al.
Plos Pathogens|September 25, 2023
CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infectionOlivia E Harwood, Lea M Matschke, Ryan V Moriarty, et al.
The Journal of Infectious Diseases|September 24, 2014
Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapyJacob D Estes, Cavan Reilly, Charles M Trubey, et al.
Eclinicalmedicine|October 19, 2023
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialPrasanna Jagannathan, Kara W Chew, Mark J Giganti, et al.
The Journal of Infectious Diseases|January 20, 2023
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19Babafemi O Taiwo, Kara W Chew, Carlee Moser, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2008
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directionsRita B Effros, Courtney V Fletcher, Kelly Gebo, et al.
Nature Medicine|February 1, 2022
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trialJeffrey S Miller, Zachary B Davis, Erika Helgeson, et al.
Pageof 17

Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Nature|January 28, 2016
Persistent HIV-1 replication maintains the tissue reservoir during therapyRamon Lorenzo-Redondo, Helen R Fryer, Trevor Bedford, et al.
Pathogens & Immunity|May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 TrialKatya C Corado, Kara W Chew, Mark J Giganti, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
CD8+ cells and small viral reservoirs facilitate post-ART control of SIV in Mauritian cynomolgus macaquesOlivia E Harwood, Lea M Matschke, Ryan V Moriarty, et al.
Plos Pathogens|September 25, 2023
CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infectionOlivia E Harwood, Lea M Matschke, Ryan V Moriarty, et al.
The Journal of Infectious Diseases|September 24, 2014
Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapyJacob D Estes, Cavan Reilly, Charles M Trubey, et al.
Eclinicalmedicine|October 19, 2023
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialPrasanna Jagannathan, Kara W Chew, Mark J Giganti, et al.
The Journal of Infectious Diseases|January 20, 2023
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19Babafemi O Taiwo, Kara W Chew, Carlee Moser, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2008
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directionsRita B Effros, Courtney V Fletcher, Kelly Gebo, et al.
Nature Medicine|February 1, 2022
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trialJeffrey S Miller, Zachary B Davis, Erika Helgeson, et al.
Pageof 17